Novartis, Arrowhead sign $2b deal for Parkinson’s RNA therapy
Longevity Technology - 02-Sep-2025Experimental RNAi drug aims to silence alpha-synuclein and slow neurodegeneration
Join the club for FREE to access the whole archive and other member benefits.
Experimental RNAi drug aims to silence alpha-synuclein and slow neurodegeneration
Researchers stress it shows association, not proof of cause
PhotoPharmics secures $6 million to advance its home-based Celeste device
It avoids common delivery problems and enters Phase 1 trials in 2025
New research reveals how Parkin, PINK1, and OMA1 act as guardians of cellular energy centres
Click on resource name for more details.
This volume has long prevailed as one of the leading resources on Parkinson's disease edited by Rajesh Pahwa
Non-profit organisation focused on the health and welfare of people living with Parkinson's disease
No blog posts found!